>
NeuroVive Pharmaceutical AB logo

NVP BTA - NeuroVive Pharmaceutical AB Share Price

SEK1 0.0  0.0%

Last Trade - 25/05/20

Sector
Healthcare
Size
Micro Cap
Market Cap £17.7m
Enterprise Value £9.76m
Revenue £10.9k
Position in Universe th / 1864
Bullish
Bearish
Unlock NVP BTA Revenue
Momentum
Relative Strength (%)
1m +36.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2.50 0.014 0.027 0.005 0.13 0.22 0.93 0.93 -38.7%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2021, Abliva ABrevenues decreased 83% to SEK18K. Net loss applicable tocommon stockholders increased 40% to SEK51.8M. Revenuesreflect a decrease in demand for the Company's products andservices due to unfavorable market conditions. Higher netloss reflects Research & Development Expense increase of43% to SEK39.7M (expense), Personnel cost increase of 35%to SEK10.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NVP BTA Revenue Unlock NVP BTA Revenue

Net Income

NVP BTA Net Income Unlock NVP BTA Revenue

Normalised EPS

NVP BTA Normalised EPS Unlock NVP BTA Revenue

PE Ratio Range

NVP BTA PE Ratio Range Unlock NVP BTA Revenue

Dividend Yield Range

NVP BTA Dividend Yield Range Unlock NVP BTA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NVP BTA EPS Forecasts Unlock NVP BTA Revenue
Profile Summary

Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.

Directors
Last Annual December 31st, 2020
Last Interim June 30th, 2021
Public Since October 3, 2008
No. of Shareholders: 12,810
No. of Employees: 9
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OMX Nordic Exchange Stockholm (Dual Listing)
Shares in Issue 403,006,798
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NVP BTA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NVP BTA
Upcoming Events for NVP BTA
Frequently Asked Questions for NeuroVive Pharmaceutical AB
What is the NeuroVive Pharmaceutical AB share price?

As of 25/05/20, shares in NeuroVive Pharmaceutical AB are trading at SEK1, giving the company a market capitalisation of £17.7m. This share price information is delayed by 15 minutes.

How has the NeuroVive Pharmaceutical AB share price performed this year?

Shares in NeuroVive Pharmaceutical AB are currently trading at SEK1 and the price has moved by -26.36% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the NeuroVive Pharmaceutical AB price has moved by -41.94% over the past year.

What are the analyst and broker recommendations for NeuroVive Pharmaceutical AB?

There are no analysts currently covering NeuroVive Pharmaceutical AB.

When will NeuroVive Pharmaceutical AB next release its financial results?

NeuroVive Pharmaceutical AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the NeuroVive Pharmaceutical AB dividend yield?

NeuroVive Pharmaceutical AB does not currently pay a dividend.

Does NeuroVive Pharmaceutical AB pay a dividend?

NeuroVive Pharmaceutical AB does not currently pay a dividend.

When does NeuroVive Pharmaceutical AB next pay dividends?

NeuroVive Pharmaceutical AB does not currently pay a dividend.

How do I buy NeuroVive Pharmaceutical AB shares?

To buy shares in NeuroVive Pharmaceutical AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of NeuroVive Pharmaceutical AB?

Shares in NeuroVive Pharmaceutical AB are currently trading at SEK1, giving the company a market capitalisation of £17.7m.

Where are NeuroVive Pharmaceutical AB shares listed? Where are NeuroVive Pharmaceutical AB shares listed?

Here are the trading details for NeuroVive Pharmaceutical AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: NVP BTA
What kind of share is NeuroVive Pharmaceutical AB?

We were not able to load our ranking data for NeuroVive Pharmaceutical AB

Is there a NeuroVive Pharmaceutical AB share price forecast 2021?

We were not able to load any forecast data for NeuroVive Pharmaceutical AB.

How can I tell whether the NeuroVive Pharmaceutical AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NeuroVive Pharmaceutical AB. Over the past six months, the relative strength of its shares against the market has been -30.55%. At the current price of SEK1, shares in NeuroVive Pharmaceutical AB are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the NeuroVive Pharmaceutical AB PE Ratio?

We were not able to find PE ratio data for NeuroVive Pharmaceutical AB.

Who are the key directors of NeuroVive Pharmaceutical AB?

NeuroVive Pharmaceutical AB's management team is headed by:

Eskil Elmer - CSO
Catharina Johansson - DCE
Magnus Hansson - OTH
Cecilia Hofvander - DIR
David Laskow-Pooley - CHM
Michele Tavecchio - OTH
Jan Tornell - DRC
David Bejker - DRC
Denise Goode - DRC
Magnus Persson - DRC
Ellen Donnelly - CEO
Who are the major shareholders of NeuroVive Pharmaceutical AB?

Here are the top five shareholders of NeuroVive Pharmaceutical AB based on the size of their shareholding:

Similar to NVP BTA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.